Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Alterations in the brain interactome of the intrinsically disordered N-terminal domain of the cellular prion protein (PrPC) in Alzheimer's disease.

Ulbrich S, Janning P, Seidel R, Matschke J, Gonsberg A, Jung S, Glatzel M, Engelhard M, Winklhofer KF, Tatzelt J.

PLoS One. 2018 May 23;13(5):e0197659. doi: 10.1371/journal.pone.0197659. eCollection 2018.

2.

The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Müller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FU, Multhaup G, Winklhofer KF, Tatzelt J.

EMBO J. 2011 May 18;30(10):2057-70. doi: 10.1038/emboj.2011.86. Epub 2011 Mar 25.

3.

High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.

Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schlüter H, Hildebrand D, Zerr I, Matschke J, Glatzel M.

Brain. 2014 Mar;137(Pt 3):873-86. doi: 10.1093/brain/awt375. Epub 2014 Feb 10.

PMID:
24519981
4.

The P's and Q's of cellular PrP-Aβ interactions.

Westaway D, Jhamandas JH.

Prion. 2012 Sep-Oct;6(4):359-63. doi: 10.4161/pri.20675. Epub 2012 Aug 9.

5.

Insoluble cellular prion protein and its association with prion and Alzheimer diseases.

Zou WQ, Zhou X, Yuan J, Xiao X.

Prion. 2011 Jul-Sep;5(3):172-8. doi: 10.4161/pri.5.3.16894. Epub 2011 Jul 1. Review.

7.

Mapping of possible prion protein self-interaction domains using peptide arrays.

Rigter A, Langeveld JP, Timmers-Parohi D, Jacobs JG, Moonen PL, Bossers A.

BMC Biochem. 2007 Apr 12;8:6.

8.

Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).

Haas LT, Kostylev MA, Strittmatter SM.

J Biol Chem. 2014 Oct 10;289(41):28460-77. doi: 10.1074/jbc.M114.584342. Epub 2014 Aug 22.

9.

Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.

Falker C, Hartmann A, Guett I, Dohler F, Altmeppen H, Betzel C, Schubert R, Thurm D, Wegwitz F, Joshi P, Verderio C, Krasemann S, Glatzel M.

J Neurochem. 2016 Apr;137(1):88-100. doi: 10.1111/jnc.13514. Epub 2016 Mar 2.

10.

Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells.

Kumar R, McClain D, Young R, Carlson GA.

J Gen Virol. 2008 Jun;89(Pt 6):1525-32. doi: 10.1099/vir.0.83358-0.

11.

Prion protein self-peptides modulate prion interactions and conversion.

Rigter A, Priem J, Timmers-Parohi D, Langeveld JP, van Zijderveld FG, Bossers A.

BMC Biochem. 2009 Nov 30;10:29. doi: 10.1186/1471-2091-10-29.

12.

The AGAAAAGA palindrome in PrP is required to generate a productive PrPSc-PrPC complex that leads to prion propagation.

Norstrom EM, Mastrianni JA.

J Biol Chem. 2005 Jul 22;280(29):27236-43. Epub 2005 May 25.

13.

Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier.

Pflanzner T, Petsch B, André-Dohmen B, Müller-Schiffmann A, Tschickardt S, Weggen S, Stitz L, Korth C, Pietrzik CU.

J Cereb Blood Flow Metab. 2012 Apr;32(4):628-32. doi: 10.1038/jcbfm.2012.7. Epub 2012 Feb 1.

14.

Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.

Um JW, Strittmatter SM.

Prion. 2013 Jan-Feb;7(1):37-41. doi: 10.4161/pri.22212. Epub 2012 Sep 17. Review.

15.

Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.

Béland M, Bédard M, Tremblay G, Lavigne P, Roucou X.

Neurobiol Aging. 2014 Jul;35(7):1537-48. doi: 10.1016/j.neurobiolaging.2014.02.001. Epub 2014 Feb 6.

PMID:
24602510
16.

Soluble Aβ aggregates can inhibit prion propagation.

Sarell CJ, Quarterman E, Yip DC, Terry C, Nicoll AJ, Wadsworth JDF, Farrow MA, Walsh DM, Collinge J.

Open Biol. 2017 Nov;7(11). pii: 170158. doi: 10.1098/rsob.170158.

17.

Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.

Bove-Fenderson E, Urano R, Straub JE, Harris DA.

J Biol Chem. 2017 Oct 13;292(41):16858-16871. doi: 10.1074/jbc.M117.789990. Epub 2017 Aug 23.

18.

Assessment of the PrPc Amino-Terminal Domain in Prion Species Barriers.

Davenport KA, Henderson DM, Mathiason CK, Hoover EA.

J Virol. 2016 Nov 14;90(23):10752-10761. doi: 10.1128/JVI.01121-16. Print 2016 Dec 1.

19.

Unaltered prion protein expression in Alzheimer disease patients.

Saijo E, Scheff SW, Telling GC.

Prion. 2011 Apr-Jun;5(2):109-16. Epub 2011 Apr 1.

20.

Immunoaffinity purification and neutralization of scrapie prions.

Gabizon R, McKinley MP, Groth D, Westaway D, DeArmond SJ, Carlson GA, Prusiner SB.

Prog Clin Biol Res. 1989;317:583-600. Review.

PMID:
2574871

Supplemental Content

Support Center